Development of interim patient-reported outcome measures for the assessment of ulcerative colitis disease activity in clinical trials
Alimentary Pharmacology & Therapeutics2015Vol. 42(10), pp. 1200–1210
Citations Over TimeTop 1% of 2015 papers
Vipul Jairath, Reena Khanna, Guangyong Zou, Larry Stitt, Mahmoud Mosli, Margaret K. Vandervoort, Geert D’Haens, William J. Sandborn, Brian G. Feagan, Barrett G. Levesque
Abstract
Patient-reported outcomes items derived from the Mayo Clinic Score combined with endoscopy as a co-primary endpoint may be an appropriate interim outcome measure for ulcerative colitis trials.
Related Papers
- Study on the safety and efficacy of three amino salicylc acid preparations for treating ulcerative colitis(2014)
- Sustained-release tablets plus mesalazine enema for ulcerative colitis(2011)
- The clinical effect of mesalazine combined with ligustrazine in treating ulcerative colitis(2011)
- Effects of Probiotics as Maintenance Therapy in Ulcerative Colitis(2011)
- → Optimization of approaches to the treatment of mild to moderate ulcerative colitis(2021)